All In Biotech

Free tool

FAERS Monitor: Caduet

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021540 or its brand name (Caduet, Amlodipine Besylate, Atorvastatin Calcium). Reports on generic versions are filed under their own applications.

Reports

4,091

Serious

2,658

65% of reports

Hospitalization

1,073

Death reported

358

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness184
  • drug ineffective178
  • nausea178
  • fatigue175
  • malaise163
  • pain148
  • dyspnoea146
  • death144
  • headache133
  • hypertension133
  • asthenia126
  • diarrhoea124
  • oedema peripheral119
  • fall118
  • pruritus106

Reports by year received

View as table
YearReports
20044
200552
2006102
2007193
2008169
2009217
2010622
2011291
2012356
2013275
2014250
2015226
2016176
2017161
2018129
2019177
2020199
2021105
202298
202389
202479
202564
202657

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,068 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
oedema peripheralSignal1195.04.2381
hypertensionSignal1333.22.7204
malaise1631.91.671
dizziness1841.91.679
fall1181.81.544
asthenia1261.71.538
pruritus1061.41.213
dyspnoea1461.31.112
pain1481.21.17
nausea1781.21.04
fatigue1751.21.04
headache1331.10.91
diarrhoea1241.00.80
death1440.90.73
drug ineffective1780.70.625

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.